Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamics of SHR4640 and Febuxostat Interaction in Hyperuricemia
NCT04157959Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Oct 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ruzinurad in hyperuricemia (2 arms), sponsored by Hengrui. Primary endpoints: Peak Plasma Concentration at Day 14 and Area under the plasma concentration versus time curve at Day 14. Status: unknown.
02
Drugs
ruzinurad
03
Conditions
hyperuricemia
Beyond the preview
Go deeper on NCT04157959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04157959.